Immunotherapy in Hepatocellular Carcinoma

Immunotherapy in Hepatocellular Carcinoma

Based on this evidence, a deep understanding of the immunological status and biological targets modulating immunological microenvironments should be quite informative for the development of future immunotherapy in HCC. From this point of view, this Special Issue will highlight the current state of t...

Full description

Bibliographic Details
Format:	eBook
Language:	English
Published:	Basel MDPI - Multidisciplinary Digital Publishing Institute 2023
Subjects:	Medicine and Nursing Oncology a disintegrin and metalloprotease 9 alpha fetoprotein response anti-VEGF inhibitor biomarkers cancer immunotherapy CD14+ cells check-point inhibitors combination immunotherapy combination therapies combination therapy copy number variations CTLA-4 effectiveness genetic alteration HCC hepatocellular carcinoma hepatocellular carcinoma (HCC) immune checkpoint blockade immune checkpoint inhibition immune checkpoint inhibitor immune phenotype immune-related adverse events (irAEs) immunotherapy liver cancer liver disease microRNAs molecular classification molecular-targeted agent mutations natural killer nivolumab oncogenic signal outcome PD-1 PD-1 antibody PD-L1 PD-L1 antibody predictive factors predictive markers programmed death 1 ligands safety stem cell marker TACE TCGA therapy resistance tissue-resident memory CD8 T cells translational approaches tyrosine kinase inhibitor unresectable hepatocellular carcinoma β-catenin
Online Access:	Open Access: DOAB: description of the publication Open Access: DOAB, download the publication

Similar Items

Recent Advances in Immunotherapy for Hepatocellular Carcinoma
by: Shigeharu Nakano, et al.
Published: (2020-03-01)

Observational Study of PD-L1, TGF-β, and Immune Cell Infiltrates in Hepatocellular Carcinoma
by: Christian Ihling, et al.
Published: (2019-02-01)

The Efficacy and Safety of Programmed Death-1 and Programmed Death Ligand 1 Inhibitors for the Treatment of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
by: Shukang He, et al.
Published: (2021-03-01)

Immunotherapy Updates in Advanced Hepatocellular Carcinoma
by: Amisha Singh, et al.
Published: (2021-04-01)

Anti-PD-1/PD-L1 Based Combination Immunotherapy to Boost Antigen-Specific CD8<sup>+</sup> T Cell Response in Hepatocellular Carcinoma
by: Julia Peña-Asensio, et al.
Published: (2021-04-01)

Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma
by: Masatoshi Kudo
Published: (2020-04-01)

The efficacy and safety of combination of PD-1 and CTLA-4 inhibitors: a meta-analysis
by: Kongju Wu, et al.
Published: (2019-10-01)

The Future of Cancer Diagnosis, Treatment and Surveillance: A Systemic Review on Immunotherapy and Immuno-PET Radiotracers
by: Virginia Liberini, et al.
Published: (2021-04-01)

Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges
by: Zuzana Macek Jilkova, et al.
Published: (2019-10-01)

Prospect of the use of checkpoint inhibitors in hepatocellular cancer treatments
by: Raufi A, et al.
Published: (2017-02-01)

Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects
by: Zhuoyan Liu, et al.
Published: (2021-10-01)

Immunotherapy in Renal Cell Carcinoma: The Future Is Now
by: Antoine Deleuze, et al.
Published: (2020-04-01)

Combination approaches with immune checkpoint blockade in cancer therapy
by: Maarten Swart, et al.
Published: (2016-11-01)

NSCLC Biomarkers to Predict Response to Immunotherapy with Checkpoint Inhibitors (ICI): From the Cells to In Vivo Images
by: Virginia Liberini, et al.
Published: (2021-09-01)

Mechanisms of PD-L1 Regulation in Malignant and Virus-Infected Cells
by: Hadia Farrukh, et al.
Published: (2021-05-01)

The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors
by: Andrew A. Davis, et al.
Published: (2019-10-01)

New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31stAnnual Meeting of the Society for Immunotherapy of Cancer, 2016
by: Prasad S. Adusumilli, et al.
Published: (2017-06-01)

Biomarkers in immune checkpoint inhibition therapy for cancer patients: what is the role of lymphocyte subsets and PD1/PD-L1?
by: Puneet Singh, et al.
Published: (2019-02-01)

Combining Radiation and Immune Checkpoint Blockade in the Treatment of Head and Neck Squamous Cell Carcinoma
by: Gregor Manukian, et al.
Published: (2019-03-01)

Mechanism and potential predictive biomarkers of immune checkpoint inhibitors in NSCLC
by: Jialin Qu, et al.
Published: (2020-07-01)

Combinational Immunotherapy for Hepatocellular Carcinoma: Radiotherapy, Immune Checkpoint Blockade and Beyond
by: Yun Hua Lee, et al.
Published: (2020-09-01)

Utilization of Immunotherapy for the Treatment of Hepatocellular Carcinoma in the Peri-Transplant Setting: Transplant Oncology View
by: Abdelrahim, M., et al.
Published: (2022)

Neuro-ophthalmic Complications of Immune Checkpoint Inhibitors: A Systematic Review
by: Yu CW, et al.
Published: (2020-11-01)

Outcomes Associated with First-Line anti-PD-1/ PD-L1 agents vs. Sunitinib in Patients with Sarcomatoid Renal Cell Carcinoma: A Systematic Review and Meta-Analysis
by: Carlo Buonerba, et al.
Published: (2020-02-01)

Clinical Features and Multiplatform Molecular Analysis Assist in Understanding Patient Response to Anti-PD-1/PD-L1 in Renal Cell Carcinoma
by: Eileen Shiuan, et al.
Published: (2021-03-01)

Gd-EOB-DTPA-MRI Could Predict WNT/β-Catenin Mutation and Resistance to Immune Checkpoint Inhibitor Therapy in Hepatocellular Carcinoma
by: Masatoshi Kudo
Published: (2020-08-01)

Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer
by: Yu Pan, et al.
Published: (2019-11-01)

Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC)
by: Wolfgang M. Brueckl, et al.
Published: (2020-12-01)

Challenges and Opportunities for Effective Cancer Immunotherapies
by: Clare Y. Slaney, et al.
Published: (2020-10-01)

Pretreatment Peripheral B Cells Are Associated With Tumor Response to Anti-PD-1-Based Immunotherapy
by: Shumin Yuan, et al.
Published: (2020-10-01)

Chinese Experts Consensus on Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer (2019 version)
by: Caicun ZHOU, et al.
Published: (2020-02-01)

Progress in Clinical Researches of PD-1/PD-L1 Checkpoint Inhibitor for  Non-small Cell Lung Cancer
by: Sixuan WU, et al.
Published: (2019-07-01)

Adaptive NK Cell Therapy Modulated by Anti-PD-1 Antibody in Gastric Cancer Model
by: Shahrokh Abdolahi, et al.
Published: (2021-09-01)

Profile of pembrolizumab in the treatment of patients with unresectable or metastatic urothelial carcinoma
by: Inokuchi J, et al.
Published: (2019-05-01)

Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors
by: Florent Peyraud, et al.
Published: (2020-06-01)

Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment
by: Yuxiao Song, et al.
Published: (2020-08-01)

High‐dose corticosteroid use and risk of hospitalization for infection in patients treated with immune checkpoint inhibitors––A nationwide register‐based cohort study
by: Signe Sørup, et al.
Published: (2021-07-01)

Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
by: Dongxu Wang, et al.
Published: (2019-04-01)

Anti-PD-1 Therapy Response Predicted by the Combination of Exosomal PD-L1 and CD28
by: Chaoxu Zhang, et al.
Published: (2020-05-01)

Primary and Acquired Resistance to Immunotherapy in Lung Cancer: Unveiling the Mechanisms Underlying of Immune Checkpoint Blockade Therapy
by: Laura Boyero, et al.
Published: (2020-12-01)